UY33897A - Inhibidores del virus de la hepatitis c - Google Patents

Inhibidores del virus de la hepatitis c

Info

Publication number
UY33897A
UY33897A UY0001033897A UY33897A UY33897A UY 33897 A UY33897 A UY 33897A UY 0001033897 A UY0001033897 A UY 0001033897A UY 33897 A UY33897 A UY 33897A UY 33897 A UY33897 A UY 33897A
Authority
UY
Uruguay
Prior art keywords
hepatitis
virus inhibitors
compounds
virus
treatment
Prior art date
Application number
UY0001033897A
Other languages
English (en)
Spanish (es)
Inventor
John A Bender
Omar D Lopez
Wang Gan
Belema Makonen
John F Kadow
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45688244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY33897A publication Critical patent/UY33897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
UY0001033897A 2011-02-07 2012-02-07 Inhibidores del virus de la hepatitis c UY33897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440086P 2011-02-07 2011-02-07
US201161467602P 2011-03-25 2011-03-25

Publications (1)

Publication Number Publication Date
UY33897A true UY33897A (es) 2012-08-31

Family

ID=45688244

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033897A UY33897A (es) 2011-02-07 2012-02-07 Inhibidores del virus de la hepatitis c

Country Status (23)

Country Link
US (2) US8552047B2 (show.php)
EP (1) EP2673271B1 (show.php)
JP (1) JP5815746B2 (show.php)
KR (1) KR20140048848A (show.php)
CN (1) CN103347878B (show.php)
AR (1) AR085327A1 (show.php)
AU (1) AU2012214767B2 (show.php)
BR (1) BR112013020042A2 (show.php)
CA (1) CA2826774A1 (show.php)
CL (1) CL2013002241A1 (show.php)
CO (1) CO6761335A2 (show.php)
EA (1) EA021538B1 (show.php)
ES (1) ES2540052T3 (show.php)
IL (1) IL227789A0 (show.php)
MA (1) MA34896B1 (show.php)
MX (1) MX2013008419A (show.php)
PE (1) PE20140302A1 (show.php)
PH (1) PH12013501543A1 (show.php)
SG (1) SG192267A1 (show.php)
TW (1) TWI542585B (show.php)
UY (1) UY33897A (show.php)
WO (1) WO2012109080A1 (show.php)
ZA (1) ZA201306720B (show.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112014010401A8 (pt) 2011-11-03 2017-12-19 Theravance Inc Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6069491B2 (ja) 2012-04-25 2017-02-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｃ型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
JP6196678B2 (ja) * 2012-10-24 2017-09-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
US9762562B2 (en) * 2013-09-13 2017-09-12 Facebook, Inc. Techniques for multi-standard peer-to-peer connection
US20160311806A1 (en) * 2013-12-11 2016-10-27 Bristol-Myers Squibb Company 4,4'-biphenyldiyl-bis-(1 h-imidazolyl) derivatives as hepatitis hcv inhibitors
CN104860931A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
NZ726343A (en) * 2014-06-12 2018-04-27 Gilead Sciences Inc Antiviral compounds
US10518123B2 (en) 2014-06-13 2019-12-31 Nautilus, Inc. Adjustable dumbbell system
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法
US11857827B2 (en) 2021-11-19 2024-01-02 Nautilus, Inc. Plate-sensing base for a connected adjustable free weight system
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679153A4 (en) 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
US20050069522A1 (en) 2002-08-12 2005-03-31 Richard Colonno Combination pharmaceutical agents as inhibitors of HCV replication
DE102004036971B4 (de) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2348332T3 (es) 2005-09-16 2010-12-02 Arrow Therapeutics Limited Derivados de bifenilo y su uso en el tratamiento de la hepatitis c.
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
BRPI0712806A2 (pt) 2006-05-30 2012-10-23 Arrow Therapeutics Ltd uso de um composto, derivado de bifenila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, produto, e, método para melhorar uma infecção por hepatite c em um paciente
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101558059B (zh) * 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2097405A2 (en) 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
CA2715400A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Heterocyclic derivatives as hepatitis c virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
BRPI0922366B8 (pt) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
SG171890A1 (en) 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
MX2011008982A (es) 2009-02-27 2011-09-15 Enata Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
KR101387274B1 (ko) 2009-03-27 2014-04-25 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 복제의 억제제
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120115918A1 (en) 2009-04-15 2012-05-10 Abbott Laboratories Anti-Viral Compounds
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
RU2528231C2 (ru) 2009-04-24 2014-09-10 Тиботек Фармасьютикалз Диариловые эфиры
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
MX363732B (es) 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010253790A1 (en) 2009-05-29 2011-12-15 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
EP2473503B1 (en) 2009-09-03 2014-07-23 Janssen R&D Ireland Bis-benzimidazole derivatives
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) * 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2010325980B2 (en) 2009-12-04 2016-04-07 National Health Research Institutes Proline derivatives
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
WO2011091532A1 (en) 2010-01-28 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
AU2010347272A1 (en) 2010-03-04 2012-09-20 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
US8609635B2 (en) 2010-03-09 2013-12-17 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
WO2011150243A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2575819A4 (en) * 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
AR081848A1 (es) 2010-06-09 2012-10-24 Presidio Pharmaceuticals Inc Inhibidores de la proteina ns5a del vhc
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012003642A1 (en) 2010-07-09 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic compounds and use thereof for treating viral diseases
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US8815849B2 (en) 2010-07-26 2014-08-26 Janssen R&D Ireland Hetero-bicyclic derivatives as HCV inhibitors
EA022127B1 (ru) 2010-08-04 2015-11-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120195857A1 (en) * 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
EP2616461A4 (en) 2010-08-26 2014-03-26 Rfs Pharma Llc POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
EP2621501A4 (en) 2010-09-29 2014-04-09 Merck Sharp & Dohme POLYCYCLIC HETEROCYCLUS DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
JP2013538831A (ja) 2010-09-29 2013-10-17 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウィルス感染治療のための四環式インドール誘導体
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CN103189371B (zh) 2010-11-04 2015-04-01 施万生物制药研发Ip有限责任公司 丙型肝炎病毒抑制剂
JP5905020B2 (ja) 2010-11-17 2016-04-20 ギリアド ファーマセット エルエルシー 抗ウイルス化合物
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US20150232455A1 (en) 2010-12-15 2015-08-20 Allan C. Krueger Anti-viral compounds
US20150031884A1 (en) 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
EP2651926A4 (en) 2010-12-15 2014-07-09 Abbvie Inc ANTI-VIRAL COMPOUNDS
WO2012083048A2 (en) 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
EP2651925A4 (en) 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
EP2651923A4 (en) 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
EP2651885A1 (en) 2010-12-16 2013-10-23 Abbvie Inc. Anti-viral compounds
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012162578A2 (en) 2011-05-26 2012-11-29 Abbvie Inc. Anti-viral compounds
WO2012162580A2 (en) 2011-05-26 2012-11-29 Abbvie Inc Anti-viral compounds
EP3059241B1 (en) 2011-05-27 2017-11-01 Achillion Pharmaceuticals, Inc. Intermediates in the preparation of a bis(benzimidazole)cyclophane derivative
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
EP2730572B1 (en) 2011-07-09 2015-09-16 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
AR085327A1 (es) 2013-09-25
JP5815746B2 (ja) 2015-11-17
IL227789A0 (en) 2013-09-30
ES2540052T3 (es) 2015-07-08
US9340520B2 (en) 2016-05-17
CO6761335A2 (es) 2013-09-30
EP2673271A1 (en) 2013-12-18
PH12013501543A1 (en) 2013-09-23
BR112013020042A2 (pt) 2016-10-25
CN103347878B (zh) 2015-05-06
AU2012214767A1 (en) 2013-09-26
US20130028859A1 (en) 2013-01-31
CL2013002241A1 (es) 2013-12-13
EA021538B1 (ru) 2015-07-30
CN103347878A (zh) 2013-10-09
TW201307333A (zh) 2013-02-16
EA201391152A1 (ru) 2013-12-30
JP2014504643A (ja) 2014-02-24
AU2012214767B2 (en) 2016-06-02
EP2673271B1 (en) 2015-05-06
US20140012020A1 (en) 2014-01-09
SG192267A1 (en) 2013-09-30
WO2012109080A1 (en) 2012-08-16
MA34896B1 (fr) 2014-02-01
ZA201306720B (en) 2015-05-27
MX2013008419A (es) 2013-09-13
PE20140302A1 (es) 2014-03-24
TWI542585B (zh) 2016-07-21
US8552047B2 (en) 2013-10-08
NZ615067A (en) 2014-12-24
KR20140048848A (ko) 2014-04-24
CA2826774A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
UY33897A (es) Inhibidores del virus de la hepatitis c
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
UY34066A (es) Inhibidores del virus de la hepatitis c
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
BR112013003101A2 (pt) inibidores do vírus da hepatite c
ECSP13012622A (es) Compuestos antivirales
BR112013002729A2 (pt) inibidores de vírus de hepatite c
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
GT201500021A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UA116087C2 (uk) Композиція для лікування вірусу гепатиту c
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
EA201391637A1 (ru) Ингибиторы вируса гепатита c
BR112014013972A2 (pt) inibidores de hcv nssa
ECSP13012438A (es) Proceso para preparar compuestos antivirales
EA201590770A1 (ru) Ингибиторы вируса гепатита с
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
BR112014015582A8 (pt) compostos antivirais
CO6321231A2 (es) Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatitis c
UA113048C2 (xx) Противірусні сполуки
CL2012001269A1 (es) Compuestos derivados de bi-imidazol di-sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar infecciones por virus de hepatitis c (vhc).
CO6290680A2 (es) Inhibidores de virus de la hepatitis c
TN2013000335A1 (en) Hepatitis c virus inhibitors
TN2013000453A1 (en) Hepatitis c virus inhibitors
CR20140273A (es) Composiciones y métodos para tratar el virus de la hepatitis c